Cabozantinib (CBZ) is a receptor tyrosine kinase (RTK) inhibitor with potent activity against multiple RTKs, including VEGFR-2 and MET, that mediate tumour survival, metastasis and angiogenesis and are also expressed by a number of cell types in bone [1], [2], [3], [4]. Here, NTRK1 is linked to neoplasm.